SHANGHAI–(BUSINESS WIRE)–EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Jerry Su, Ph.D. as the Chief Technology Officer of EpimAb. Dr. Su joined EpimAb in December 2019 as Senior VP, CMC and led the completion of EpimAb’s early CMC development facility in Suzhou BioBay. In this newly created role, Dr. Su will continue to oversee the company’s CMC development and manufacturing operations.
“Since he joined EpimAb, Jerry contributed significantly to the organizational growth of EpimAb by successfully completing our fully functional CMC development and manufacturing facility in Suzhou BioBay ahead of plan,” said Dr. Chengbin Wu, founder and CEO of EpimAb Biotherapeutics. “We are delighted to promote Jerry to this new role and look forward to his continued contribution and leadership in driving manufacturing strategy as we rapidly advance our pipeline of novel bispecific antibodies.”
“I am honored to serve in this new role alongside the wonderful team of scientists and industry leaders to scale EpimAb’s efforts in driving bispecifics innovation in China and worldwide,” said Dr. Su. “With three assets in clinical development and multiple preclinical programs to come, efficient R&D and manufacturing operations as well as regulatory strategies are more important than ever before. I am excited to lead our efforts in some of these key areas and execute on the potential of our bispecific platform technologies to drive value for partners and patients.”
Dr. Su brings to EpimAb over 20 years of technical and leadership experience in pharmaceutical R&D, manufacturing, and CMC operations with global and China pharmaceutical companies, including Pfizer, Genzyme, Merck, and Hengrui, as well as CDMO Wuxi Biologics. Before joining EpimAb, he was CEO of Zhejiang Huahai Biopharmaceuticals Co. in Hangzhou. Dr. Su has broad experience in cell culture, process development, technology transfer, validation, manufacturing and compliance operations, with strong hands-on regulatory experience in new drug license submission as well as post-approval product support dealing with regulatory inspection, response preparation and change management. Dr. Su received a Ph.D. in chemical engineering with a minor in statistics from West Virginia University, an M.S. in biochemical engineering from Beijing University of Chemical Technology, and a B.S. in chemical engineering from Tianjin University.
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou, China. Based on a proprietary unique and efficient bispecific antibody technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin), EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. For further information, please visit www.epimab.com
Contacts
EpimAb Biotherapeutics
In the U.S.:
Dr. Stephan Lensky, COO/CBO
Direct: +1 978-870-6276
Stephan.lensky@epimab.com
In China:
Dr. David Gu, CFO
Direct: +86-21-61951011
David.gu@epimab.com
Dr. Jason Tang, BD Director
Direct: +86-21-61951014
yesheng.tang@epimab.com
Media Inquiries
MacDougall
Amanda Houlihan or Emily Wong
+1 781-235-3060
epimab@macbiocom.com
